BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

370 related articles for article (PubMed ID: 3332155)

  • 1. Difference in kinetics of hematopoietic reconstitution between ALL and ANLL after autologous bone marrow transplantation with marrow treated in vitro with mafosfamide (ASTA Z 7557).
    Douay L; Laporte JP; Mary JY; Lopez M; Lemonnier MP; Stachowiak J; Benitez O; Deloux J; Najman A; Salmon C
    Bone Marrow Transplant; 1987 Jun; 2(1):33-43. PubMed ID: 3332155
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Differential sensitivity of adherent CFU-blast, CFU-mix, BFU-E, and CFU-GM to mafosfamide: implications for adjusted dose purging in autologous bone marrow transplantation.
    Carlo-Stella C; Mangoni L; Almici C; Garau D; Craviotto L; Piovani G; Caramatti C; Rizzoli V
    Exp Hematol; 1992 Mar; 20(3):328-33. PubMed ID: 1568448
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of recombinant human stem cell factor on mafosfamide-treated bone marrow clonogenic cells.
    Carlo-Stella C; Mangoni L; Almici C; Caramatti C; Rizzoli V
    Stem Cells; 1993 Jul; 11 Suppl 2():170-4. PubMed ID: 7691323
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recovery of CFU-GM from cryopreserved marrow and in vivo evaluation after autologous bone marrow transplantation are predictive of engraftment.
    Douay L; Gorin NC; Mary JY; Lemarie E; Lopez M; Najman A; Stachowiak J; Giarratana MC; Baillou C; Salmon C
    Exp Hematol; 1986 Jun; 14(5):358-65. PubMed ID: 3519263
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Analysis of factors predicting speed of hematologic recovery after transplantation with 4-hydroperoxycyclophosphamide-purged autologous bone marrow grafts.
    Rowley SD; Piantadosi S; Marcellus DC; Jones RJ; Davidson NE; Davis JM; Kennedy J; Wiley JM; Wingard JR; Yeager AM
    Bone Marrow Transplant; 1991 Mar; 7(3):183-91. PubMed ID: 2059755
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The use of recombinant cytokines for enhancing immunohematopoietic reconstitution following bone marrow transplantation. II. The influence of lymphokines on CFU-GM colonies from human untreated, ASTA-Z or Campath-1M treated bone marrow.
    Mumcuoglu M; Naparstek E; Slavin S
    Bone Marrow Transplant; 1990 Mar; 5(3):153-8. PubMed ID: 2184907
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hemopoietic reconstitution after repeated autologous transplantation with mafosfamide-purged marrow.
    Beaujean F; Hartmann O; Benhamou E; Lemerle J; Duedari N
    Bone Marrow Transplant; 1989 Sep; 4(5):537-41. PubMed ID: 2790332
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Bone marrow autotransplantation in acute myeloblastic leukemia in its first complete remission. The clinical results in 41 patients].
    Tomás JF; Gómez-García de Soria V; Pinilla I; Lamana M; Figuera A; Arranz R; Cámara R; Fernández-Villalta MJ; Alegre A; Fernández-Rañada JM
    Med Clin (Barc); 1997 Feb; 108(6):201-6. PubMed ID: 9102484
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vitro purging of bone marrow with mafosfamide synergizes with in vivo chemotherapy to delay the hematological recovery in a murine model of autologous bone marrow transplantation.
    Lopez M; Mary JY; Sainteny F
    Exp Hematol; 1993 Feb; 21(2):311-8. PubMed ID: 8425567
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Engraftment with peripheral blood stem cells using noncontrolled-rate cryopreservation: comparison with autologous bone marrow transplantation.
    Rosenfeld CS; Gremba C; Shadduck RK; Zeigler ZR; Nemunaitis J
    Exp Hematol; 1994 Mar; 22(3):290-4. PubMed ID: 7509292
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of lymphocyte subsets after autologous bone marrow transplantation with marrow treated by ASTA Z 7557 in acute leukemia: incidence of the in vitro treatment.
    Le Blanc G; Douay L; Laporte JP; Dominh A; Deloux J; Najman A; Duhamel G; Gorin NC
    Exp Hematol; 1986 Jun; 14(5):366-71. PubMed ID: 3519264
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Interleukin-3 followed by GM-CSF for delayed engraftment after autologous bone marrow transplantation.
    Crump M; Couture F; Kovacs M; Saragosa R; McCrae J; Brandwein J; Huebsch L; Beauregard-Zollinger L; Keating A
    Exp Hematol; 1993 Mar; 21(3):405-410. PubMed ID: 8440338
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Proliferative response of human marrow myeloid progenitor cells to in vivo treatment with granulocyte colony-stimulating factor alone and in combination with interleukin-3 after autologous bone marrow transplantation.
    Lemoli RM; Fortuna A; Fogli M; Gherlinzoni F; Rosti G; Catani L; Gozzetti A; Miggiano MC; Tura S
    Exp Hematol; 1995 Dec; 23(14):1520-6. PubMed ID: 8542941
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Alterations in both the hematopoietic microenvironment and the progenitor cell population follow the recovery from myeloablative therapy and bone marrow transplantation.
    Novitzky N; Mohamed R
    Exp Hematol; 1995 Dec; 23(14):1661-6. PubMed ID: 8542962
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Establishment of a reliable experimental procedure for bone marrow purging with mafosfamide (ASTA Z 7557).
    Douay L; Mary JY; Giarratana MC; Najman A; Gorin NC
    Exp Hematol; 1989 Jun; 17(5):429-32. PubMed ID: 2653856
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The additive effect of peripheral blood stem cells, harvested with low-dose cyclophosphamide, to autologous bone marrow reinfusion on hematopoietic reconstitution after ablative chemotherapy in breast cancer patients with localized disease.
    de Graaf H; Mulder NH; Willemse PH; van der Graaf WT; Sleijfer DT; Zijlstra JG; Elias M; Sibinga CT; Vellenga E; de Vries EG
    Anticancer Res; 1995; 15(6B):2851-6. PubMed ID: 8669878
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacological-mediated purging with mafosfamide in acute and chronic myeloid leukemias. The Italian Study Group.
    Rizzoli V; Mangoni L
    Prog Clin Biol Res; 1990; 333():21-36; discussion 37-8. PubMed ID: 2308982
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Experimental bases of the in vitro treatment of leukemic bone marrow by a derivative of cyclophosphamide: ASTA Z 7557].
    Douay L; Gorin NC; Mary JY; Duhamel G
    C R Acad Sci III; 1985; 301(6):303-8. PubMed ID: 3928107
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Natural killer cell regeneration after transplantation with mafosfamide purged autologous bone marrow.
    Almici C; Manoni L; Carlo-Stella C; Garau D; Cottafavi L; Rizzoli V
    Bone Marrow Transplant; 1995 Jul; 16(1):95-101. PubMed ID: 7581136
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Progenitor cell numbers (CFU-GM, CFU-D, and CFU-Mix) and hemopoietic recovery following autologous marrow transplantation.
    Stewart FM; Kaiser DL; Ishitani KP; Pirsch GW; Niskanen E
    Exp Hematol; 1989 Oct; 17(9):974-80. PubMed ID: 2673831
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.